Proteome Sciences plc
ISO 9001 : 2008 Certification
9th March, 2009 Proteome Sciences plc is pleased to announce that it has
received ISO 9001:2008 certification from the German Society for Certification
of Management Systems for its facilities in Frankfurt, Germany. This
certification covers Proteome Sciences' biomarker activities, rapid assay
development, chemical and peptide synthesis and isobaric tagging development
and production.
The Frankfurt facility was specifically designed to deliver a growing product
line of isobaric Tandem Mass Tags® (TMT®) for quantitative mass spectrometry
and to undertake biomarker programmes for customers.
Proteome Sciences now provides a comprehensive range of contract biomarker
services under ISO 9001: 2008 for discovery and validation of protein and
peptide biomarkers, for rapid development of mass spectrometry based assays and
for the measurement of protein and peptide drugs and their metabolites in
pharmacokinetics.
The ISO 9001:2008 certification is an important milestone for the company in
supporting the global marketing strategy through the expansion of its high
quality services and products based on the proprietary isobaric Tandem Mass Tag
® technology and from PS Biomarker Services™ available through the ProteoSHOP®
platform.
Christopher Pearce, Chief Executive Officer of Proteome Sciences, commented:
"We have made a considerable investment in time and effort to establish the
highest international standard of quality management systems into our biomarker
services and we are delighted to be one of the first companies globally to be
awarded ISO 9001:2008 accreditation. This further underpins our compelling TMT®
isobaric tagging products and allows us to more comprehensively exploit the
fast growing field of biomarker qualification and mass spectrometry assays
through the provision of ISO certified biomarker services for our customers.
"It is highly opportune timing to obtain the ISO 9001:2008 standard, with
isobaric Tandem Mass Tag® technology at the point where pharmaceutical
developers can use biomarkers as part of the drug development decision-making
process and when global regulators require increasing biomarker data to support
drug approval.
"Biomarkers are increasingly a key part of early disease detection, drug
development and disease management and our expertise addresses all of these
applications."
Ends
For further information please contact:
Proteome Sciences plc Tel: +44 (0)1932 865065
www.proteomics.com James Malthouse, Finance Director
Christopher Pearce, Chief Executive
Officer
Dr. Ian Pike, Chief Business Officer
Public Relations
IKON Associates Coast Communications
Adrian Shaw Matt Baldwin
Tel: +44 (0)1483 535102 Tel: +44 (0)1233 503200
Mobile: +44 (0)797 9900733 Mobile: +44 (0)7930 439739
Email: adrian@ikonassociates.com Email: matt@coastcommunications.com
Nominated Adviser
Teathers
Shaun Dobson / Claes Spång
Tel: +44 (0)20 7426 9000
About Proteome Sciences:
Proteome Sciences is a leading biomarker CRO providing protein biomarker
discovery, validation and assay development services. The Company's MS
Biomarker Assay system (MBA) uses its proprietary isobaric Tandem Mass Tags
(TMT®) and reference materials combined with isotope dilution mass
spectrometry. Highly multiplexed assays can be developed in weeks and are
suitable for screening 10's to 100's of candidate biomarkers in validation
studies. Assays for validated biomarkers can be rapidly developed using the
same isotope dilution mass spectrometry format, or can be transferred for
immunoassay development.
The Company's own research is focused on neurological and neurodegenerative
conditions and it has discovered and patented blood biomarkers in stroke, brain
damage, cancers, transplant rejection and Alzheimer's disease. Proteome
Sciences based in Cobham, UK has facilities in London and Frankfurt.